Comparative Pharmacology
Head-to-head clinical analysis: EQUAGESIC versus NOLUDAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EQUAGESIC versus NOLUDAR.
EQUAGESIC vs NOLUDAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Equagesic is a combination of aspirin and meprobamate. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and COX-2, reducing prostaglandin synthesis. Meprobamate potentiates GABA-A receptor activity, producing anxiolytic and sedative effects.
Barbiturate that enhances GABA-A receptor activity by prolonging chloride channel opening, leading to CNS depression.
Adults: 1 tablet (200 mg meprobamate, 25 mg ethoheptazine citrate, 325 mg aspirin) orally 3 or 4 times daily.
250-500 mg orally at bedtime, with a maximum dose of 1000 mg daily.
None Documented
None Documented
Meprobamate: 10-12 hours in healthy adults, prolonged in liver disease; Aspirin: low doses 2-3 hours, anti-inflammatory doses 15-30 hours (saturable elimination).
25-35 hours
Meprobamate: renal (10% as unchanged drug, 80-90% as hydroxylated metabolites); Aspirin: renal (dose-dependent, 50-80% as salicyluric acid, 10% as unchanged salicylate at acidic pH).
Primarily renal as metabolites; <5% unchanged. Biliary/fecal elimination is negligible.
Category C
Category C
Sedative-Hypnotic
Sedative-Hypnotic